This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
by Zacks Equity Research
McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.
Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss
by Zacks Equity Research
Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.
CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.
LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up
by Zacks Equity Research
LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.
Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.
PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1
by Zacks Equity Research
PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas
by Zacks Equity Research
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.
Medtronic InterStim System Shows Five-Year Positive Results
by Zacks Equity Research
Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).
Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is on a healthy growth trajectory of late and has rallied 17.7% over the past three months.
BioTelemetry (BEAT) Acquires LifeWatch for $280 Million
by Zacks Equity Research
BioTelemetry Inc. (BEAT) enhances its position in the wireless medicine space, enlarges product profile and customer base in cardiac monitoring and diagnostic services with LifeWatch buyout.